<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37311649</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.</ArticleTitle><Pagination><StartPage>e602</StartPage><EndPage>e612</EndPage><MedlinePgn>e602-e612</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207483</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Current scales used in amyotrophic lateral sclerosis (ALS) attempt to summarize different functional domains or "dimensions" into 1 overall score, which may not accurately characterize the individual patient's disease severity or prognosis. The use of composite score risks declaring treatments ineffective if not all dimensions of ALS disease progression are affected equally. We aimed to develop the ALS Impairment Multidomain Scale (AIMS) to comprehensively characterize disease progression and increase the likelihood of identifying effective treatments.</AbstractText><AbstractText Label="METHODS">The Revised ALS Functional Rating Scale (ALSFRS-R) and a preliminary questionnaire, based on literature review and patient input, were completed online by patients from the Netherlands ALS registry at bimonthly intervals over a period of 12 months. A 2-week test-retest, factor analysis, Rasch analysis, and a signal-to-noise optimization strategy were performed to create a multidomain scale. Reliability, longitudinal decline, and associations with survival were evaluated. The sample size required to detect a 35% reduction in progression rate over 6 or 12 months was assessed for a clinical trial that defines the ALSFRS-R or AIMS subscales as a primary endpoint family.</AbstractText><AbstractText Label="RESULTS">The preliminary questionnaire, consisting of 110 questions, was completed by 367 patients. Three unidimensional subscales were identified, and a multidomain scale was constructed with 7 bulbar, 11 motor, and 5 respiratory questions. Subscales fulfilled Rasch model requirements, with excellent test-retest reliability of 0.91-0.94 and a strong relationship with survival (<i>p</i> &lt; 0.001). Compared with the ALSFRS-R, signal-to-noise ratios were higher as patients declined more uniformly per subscale. Consequently, the estimated sample size reductions achieved with the AIMS compared with those achieved with the ALSFRS-R were 16.3% and 25.9% for 6-month and 12-month clinical trials, respectively.</AbstractText><AbstractText Label="DISCUSSION">We developed the AIMS, consisting of unidimensional bulbar, motor, and respiratory subscales, which may characterize disease severity better than a total score. AIMS subscales have high test-retest reliability, are optimized to measure disease progression, and are strongly related to survival time. The AIMS can be easily administered and may increase the likelihood of identifying effective treatments in ALS clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Jongh</LastName><ForeName>Adriaan D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-3658-3397</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><Identifier Source="ORCID">0000-0002-7132-5967</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Leonhard A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-5221-5095</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunte</LastName><ForeName>Tommy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beelen</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meijden</LastName><ForeName>Conny</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser-Meily</LastName><ForeName>Johanna M A</ForeName><Initials>JMA</Initials><Identifier Source="ORCID">0000-0002-5955-8012</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruitwagen</LastName><ForeName>Esther T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (A.D.d.J., R.P.A.v.E., L.A.B., T.M.B., M.A.v.E., J.H.V., L.H.v.d.B.), UMC Utrecht Brain Center, University Medical Center Utrecht; Department of Neurology (A.D.d.J.), Tergooi Hospital, Blaricum; Biostatistics &amp; Research Support (R.P.A.v.E.), Julius Center for Health Sciences and Primary Care, Department of Rehabilitation, Physical Therapy Science and Sports (L.A.B., A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, and Center of Excellence for Rehabilitation Medicine (A.B., J.M.A.V.-M., E.T.K.), UMC Utrecht Brain Center, University Medical Center Utrecht, and De Hoogstraat Rehabilitation; and ALS Patients Connected (C.v.d.M.), Bilthoven, the Netherlands. lberg@umcutrecht.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2023 Aug 8;101(6):243-244</RefSource><PMID Version="1">37311651</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37311649</ArticleId><ArticleId IdType="pmc">PMC10424842</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207483</ArticleId><ArticleId IdType="pii">WNL.0000000000207483</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/s0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661-670. doi:10.1038/nrneurol.2014.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21. doi:10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schroder CD, Tan HHG, et al. . Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. J Neurol Neurosurg Psychiatry. 2020;91(1):75-81. doi:10.1136/jnnp-2019-321138</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321138</ArticleId><ArticleId IdType="pubmed">31558653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265-267. doi:10.1212/01.wnl.0000194316.91908.8a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chio A. Evidence of multidimensionality in the ALSFRS-R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340-1345. doi:10.1136/jnnp-2012-304701</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. . An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3-4):300-307. doi:10.1080/21678421.2021.1879865</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(5):381-385. doi:10.1136/jnnp-2016-314661</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017;264(7):1413-1420. doi:10.1007/s00415-017-8538-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8538-4</ArticleId><ArticleId IdType="pmc">PMC5502060</ArticleId><ArticleId IdType="pubmed">28608303</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al. . Development and validation of the Rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS). JAMA Neurol. 2020;77(4):480-488. doi:10.1001/jamaneurol.2019.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 1989;8(3):142-150. doi:10.1159/000110176</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110176</ArticleId><ArticleId IdType="pubmed">2725806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimura-Kiyono C, Kimura F, Ishida S, et al. . Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1244-1249. doi:10.1136/jnnp-2011-300141</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300141</ArticleId><ArticleId IdType="pubmed">21921087</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Macklin EA, Myers KJ, et al. . Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). Eur J Neurol. 2018;25(7):907-e66. doi:10.1111/ene.13638</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13638</ArticleId><ArticleId IdType="pmc">PMC6005752</ArticleId><ArticleId IdType="pubmed">29577526</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleman J, Kruitwagen-van Reenen ET, Bakers J, et al. . Using patient-reported symptoms of dyspnea for screening reduced respiratory function in patients with motor neuron diseases. J Neurol. 2020;267(11):3310-3318. doi:10.1007/s00415-020-10003-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10003-5</ArticleId><ArticleId IdType="pmc">PMC7578163</ArticleId><ArticleId IdType="pubmed">32577867</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22(3):328-333. doi:10.1002/ana.410220308</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410220308</ArticleId><ArticleId IdType="pubmed">3118763</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt S, Petri S, Dengler R, Heinze HJ, Vielhaber S. Dyspnea in amyotrophic lateral sclerosis: rasch-based development and validation of a patient-reported outcome (DALS-15). J Pain Symptom Manage. 2018;56(5):736-745.e2. doi:10.1016/j.jpainsymman.2018.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2018.08.009</ArticleId><ArticleId IdType="pubmed">30145215</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. . Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-1226. doi:10.1212/wnl.0b013e3181bc0141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e3181bc0141</ArticleId><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12(9):526-538. doi:10.1038/nrneurol.2016.111</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.111</ArticleId><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. NICE guideline motor neuron disease: assessment and management [online]. Accessed June 1, 2019. nice.org.uk/guidance/ng42.</Citation></Reference><Reference><Citation>Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017;134:1409-1441. doi:10.1016/bs.irn.2017.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2017.04.009</ArticleId><ArticleId IdType="pubmed">28805578</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, Peters SM, et al. . Incidence, prevalence, and geographical clustering of motor neuron disease in the Netherlands. Neurology. 2021;96(8):e1227-e1236. doi:10.1212/wnl.0000000000011467</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000011467</ArticleId><ArticleId IdType="pmc">PMC8055340</ArticleId><ArticleId IdType="pubmed">33472922</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, de Jong SW, van Doormaal PT, et al. . Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82(10):1165-1170. doi:10.1136/jnnp.2011.244939</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2011.244939</ArticleId><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975-1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Castor EDC. (2019). Castor Electronic Data Capture. [online] Available at: https://castoredc.com.</Citation></Reference><Reference><Citation>Linacre JM. Rasch analysis of rank-ordered data. J Appl Meas. 2006;7(1):129-139.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385155</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters GN. A Rasch model for partial credit scoring. Psychometrika. 1982;47(2):149-174. doi:10.1007/bf02296272</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf02296272</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Hermans MC, Faber CG, Gorson KC, Merkies IS, Thonnard JL; PeriNomS Study Group. Rasch-ionale for neurologists. J Peripher Nerv Syst. 2015;20(3):260-268. doi:10.1111/jns.12122</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12122</ArticleId><ArticleId IdType="pubmed">26115370</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van den Berg LH, van Eijk RPA. Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials. J Neurol Neurosurg Psychiatry. 2020;92(5):569-570. doi:10.1136/jnnp-2020-325253</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325253</ArticleId><ArticleId IdType="pubmed">33229452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ard MC, Edland SD. Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis. 2011;26(suppl 3):369-377. doi:10.3233/jad-2011-0062</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-2011-0062</ArticleId><ArticleId IdType="pmc">PMC3568927</ArticleId><ArticleId IdType="pubmed">21971476</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy BC, Schoenfeld D. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve. 2012;46(4):506-511. doi:10.1002/mus.23392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23392</ArticleId><ArticleId IdType="pubmed">22987690</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Multiple endpoints in clinical trials guidance for industry [online]. Accessed April 14, 2022. fda.gov/media/102657/download.</Citation></Reference><Reference><Citation>Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(5):962-973. doi:10.1093/brain/124.5.962</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/124.5.962</ArticleId><ArticleId IdType="pubmed">11335698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone E, De Sanctis R, Fanelli L, et al. . Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients. Neuromuscul Disord. 2014;24(4):347-352. doi:10.1016/j.nmd.2014.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2014.01.003</ArticleId><ArticleId IdType="pubmed">24491485</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9(1):76-83. doi:10.1002/mds.870090112</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870090112</ArticleId><ArticleId IdType="pubmed">8139608</ArticleId></ArticleIdList></Reference><Reference><Citation>Rethnam V, Bernhardt J, Johns H, et al. . Look closer: the multidimensional patterns of post-stroke burden behind the modified Rankin scale. Int J Stroke. 2021;16(4):420-428. doi:10.1177/1747493020951941</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1747493020951941</ArticleId><ArticleId IdType="pubmed">32854602</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010;2(4):24. doi:10.1186/alzrt48</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt48</ArticleId><ArticleId IdType="pmc">PMC2949590</ArticleId><ArticleId IdType="pubmed">20796301</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Chio A, Merrill C, et al. . Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone study 19. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171. doi:10.1136/jnnp-2020-323271</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323271</ArticleId><ArticleId IdType="pmc">PMC7841496</ArticleId><ArticleId IdType="pubmed">33109706</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et al. . Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762-772. doi:10.1007/s13311-016-0508-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. . Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-930. doi:10.1056/nejmoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Review Report: Edaravone (Radicava). Mitsubishi Tanabe Pharma Corporation; 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31211530</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groenestijn AC, Schr&#xf6;der CD, van Eijk RPA, et al. . Aerobic exercise therapy in ambulatory patients with ALS: a randomized controlled trial. Neurorehabil Neural Repair. 2019;33(2):153-164. doi:10.1177/1545968319826051</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1545968319826051</ArticleId><ArticleId IdType="pubmed">30744529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristl R, Urach S, Rosenkranz G, Posch M. Methods for the analysis of multiple endpoints in small populations: a review. J Biopharm Stat. 2019;29:1-29. doi:10.1080/10543406.2018.1489402</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10543406.2018.1489402</ArticleId><ArticleId IdType="pubmed">29985752</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SR, Rubin D, Follmann D, et al. . Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800-806. doi:10.1093/cid/civ495</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ495</ArticleId><ArticleId IdType="pmc">PMC4542892</ArticleId><ArticleId IdType="pubmed">26113652</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, van den Berg LH, Lu Y. Composite endpoint for ALS clinical trials based on patient preference: patient-ranked order of function (PROOF). J Neurol Neurosurg Psychiatry. 2021;93(5):539-546. doi:10.1136/jnnp-2021-328194</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328194</ArticleId><ArticleId IdType="pmc">PMC9016230</ArticleId><ArticleId IdType="pubmed">34921121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizopoulos D, Ghosh P. A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event. Stat Med. 2011;30(12):1366-1380. doi:10.1002/sim.4205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4205</ArticleId><ArticleId IdType="pubmed">21337596</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro J, Bates D, DebRoy S, Sarkar D, Team RC. Nlme: linear and nonlinear mixed effects models. 2013.</Citation></Reference><Reference><Citation>van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333-341. doi:10.2147/clep.s153196</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/clep.s153196</ArticleId><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>